West Pharmaceutical Services Inc. (WST) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
West Pharmaceutical Services Inc. (WST) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (36% profit margin, 18% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How WST Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | 35.9% | 19% | $493.7M | $468.9M | 17.9% |
| FY 2024 | $2.89B | 34.5% | 19.7% | $492.7M | $276.4M | 18.8% |
| FY 2023 | $2.95B | 44% | 22.9% | $593.4M | $643.8M | 5.5% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring WST)
- ✓Live walkthrough of WST's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
WST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on WST today. View full Setup Ledger →
WST Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is West Pharmaceutical Services Inc. (WST)?
In FY 2025 (10-K), WST converted $3.1B of revenue into a 35.9% gross margin, 19% operating margin, and $468.9M in free cash flow (15.3% FCF margin).